Sarepta Therapeutics Hits Day Low of $15.97 Amid Price Pressure

Sarepta Therapeutics, Inc. has experienced a significant decline today, with the stock dropping by 7.72% and reaching an intraday low of USD 15.97. This performance marks a continuation of the company's struggles, as it has underperformed against the S&P 500 across various time frames. Over the past year, Sarepta has seen a staggering decline of 56.94%, while the S&P 500 has gained 28.2%. In terms of financial metrics, Sarepta's market capitalization stands at USD 1,749 million, categorizing it as a small-cap company. The firm has reported a notable operating cash flow of USD 158.22 million, which is its highest to date. Additionally, the raw material costs have decreased by 4.39% year-over-year, and the inventory turnover ratio is at a high of 0.89 times. However, the company faces challenges, including a significant drop in profits, which have fallen by 166% over the past year. With institutional holdings at 100%, Sarepta's stock remains a focal point in the pharmaceuticals and biotechnology sector, despite its recent performance challenges.